Douglas Mayers
Overview
Explore the profile of Douglas Mayers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
332
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gish R, Asselah T, Squires K, Mayers D
Antivir Chem Chemother
. 2022 Nov;
30:20402066221138705.
PMID: 36423233
Chronic hepatitis B virus (HBV) infection affects 240 to 300 million people worldwide. In the nucleus of infected hepatocytes, the HBV genome is converted to covalently closed circular DNA (cccDNA),...
2.
Vince B, Hill J, Lawitz E, ORiordan W, Webster L, Gruener D, et al.
J Hepatol
. 2014 Jan;
60(5):920-7.
PMID: 24434503
Background & Aims: Samatasvir is a pan-genotypic inhibitor of the hepatitis C (HCV) non-structural protein 5A (NS5A). This study evaluated the antiviral activity, pharmacokinetics and safety of samatasvir monotherapy in...
3.
Lalezari J, Box T, ORiordan W, Mehra P, Nguyen T, Poordad F, et al.
Antivir Ther
. 2013 Feb;
18(6):755-64.
PMID: 23439365
Background: IDX184 is a liver-targeted nucleotide prodrug that selectively inhibits HCV NS5B polymerase. Methods: This randomized, double-blind, placebo-controlled, ascending-dose study investigated the antiviral activity, safety and pharmacokinetics of IDX184 plus...
4.
Lalezari J, Asmuth D, Casiro A, Vargas H, Lawrence S, Dubuc-Patrick G, et al.
Antimicrob Agents Chemother
. 2012 Oct;
56(12):6372-8.
PMID: 23070151
IDX184 is a liver-targeted prodrug of 2'-methylguanosine (2'-MeG) monophosphate. This study investigated the safety, tolerability, antiviral activity, and pharmacokinetics of IDX184 as a single agent in treatment-naïve patients with genotype-1...
5.
de Bruijne J, van Vliet A, Weegink C, Mazur W, Wiercinska-Drapalo A, Simon K, et al.
Antivir Ther
. 2012 Mar;
17(4):633-42.
PMID: 22427481
Background: The addition of direct-acting antivirals to pegylated interferon-α plus ribavirin for the treatment of chronic HCV infection can result in an increased sustained viral response rate and may permit...
6.
Kemal K, Ramirez C, Burger H, Foley B, Mayers D, Klimkait T, et al.
AIDS Res Hum Retroviruses
. 2012 Feb;
28(12):1766-74.
PMID: 22364185
Multidrug-resistant (MDR) HIV-1 presents a challenge to the efficacy of antiretroviral therapy (ART). To examine mechanisms leading to MDR variants in infected individuals, we studied recombination between single viral genomes...
7.
Zala C, St Clair M, Dudas K, Kim J, Lou Y, White S, et al.
Antimicrob Agents Chemother
. 2012 Feb;
56(5):2570-5.
PMID: 22314532
GSK2248761 is a novel, once-daily (QD), next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) with activity against efavirenz-resistant strains. Two phase I/IIa, double-blind, randomized, placebo-controlled studies investigated the antiviral activity, safety, and...
8.
Palmer S, Boltz V, Chow J, Martinson N, McIntyre J, Gray G, et al.
Antivir Ther
. 2012 Feb;
17(2):327-36.
PMID: 22293443
Background: In the Treatment Options Preservation Study (TOPS) trial, 4 or 7 days of Combivir (CBV; zidovudine/lamivudine) with maternal single-dose nevirapine (sdNVP) significantly reduced the emergence of NVP resistance as...
9.
Piscitelli S, Kim J, Gould E, Lou Y, White S, de Serres M, et al.
Br J Clin Pharmacol
. 2012 Feb;
74(2):336-45.
PMID: 22288567
Aim: To evaluate potential drug interactions with antiretroviral therapies or supportive therapies for use in conjunction with the once daily, next generation non-nucleoside reverse transcriptase inhibitor GSK2248761 in patients with...
10.
Zhou X, Pietropaolo K, Chen J, Khan S, Sullivan-Bolyai J, Mayers D
Antimicrob Agents Chemother
. 2010 Nov;
55(1):76-81.
PMID: 21060109
IDX184 is a nucleotide prodrug designed to enhance formation in the liver of the active triphosphate of 2'-methylguanosine (2'-MeG), a potent and specific polymerase inhibitor of the hepatitis C virus...